First patient dosed in Annexin's Phase 2 study in retinal vein occlusion.
STOCKHOLM (8 November 2022) - Annexin Pharmaceuticals AB (publ) (Nasdaq First North Growth market) announces today that the first patient with retinal vein occlusion (RVO) has been dosed in the Company’s Phase 2 clinical study with ANXV. RVO is one of the most common causes of blindness. Authorized drugs for treatment of RVO are injected directly into the eye and have no direct effect on the blockage of blood vessels that causes the disease. By contrast, the Company’s drug candidate ANXV, which is administered intravenously, has the potential to directly counteract the blockage of